While our retrospective cohort analysis provides valuable insights into the association of SGLT2 inhibitors to the risk of AF when compared with DPP4 inhibitors in Medicare beneficiaries, several limitations must be acknowledged to contextualize our findings. Here, SLC5A2 is linked to atrial fibrillation.